β-Amyrin acetate and β-Amyrin palmitate as antidyslipidemic agents from Wrightia tomentosa leaves

Maurya, Ranjani; Srivastava, Anuj; Shah, Priyanka; Siddiqi, M I; Rajendran, S M; Puri, Anju; Yadav, P P

dc.contributor.author	Maurya, Ranjani
dc.contributor.author	Srivastava, Anuj
dc.contributor.author	Shah, Priyanka
dc.contributor.author	Siddiqi, M I
dc.contributor.author	Rajendran, S M
dc.contributor.author	Puri, Anju
dc.contributor.author	Yadav, P P
dc.date.accessioned	2012-09-10T06:50:55Z
dc.date.available	2012-09-10T06:50:55Z
dc.date.issued	2012
dc.identifier.citation	Phytomedicine2012, 19(8–9), 682–685	en
dc.identifier.uri	http://hdl.handle.net/123456789/909
dc.description.abstract	The ethanolic extract and fractions of Wrightia tomentosa Roem. & Schult (Apocynaceae) leaves were tested in vivo for their antidyslipidemic activity in high fat diet (HFD) induced dyslipidemic hamsters. Activity guided isolation resulted in identification of antidyslipidemic compounds β-AA and β-AP. Compounds β-AA and β-AP decrease the levels of LDL by 36% and 44%, and increase the HDL-C/TC ratio by 49% and 28% respectively at a dose of 10mg/kg. In addition, the isolated compounds β-AA and β-AP showed significant HMGCoA- reductase inhibition which was further established by docking studies.	en
dc.format.extent	575303 bytes
dc.format.mimetype	application/pdf
dc.language.iso	en	en
dc.relation.ispartofseries	CDRI Communication No. 8220	en
dc.subject	Wrightia tomentosa	en
dc.subject	β-amyrin acetate	en
dc.subject	β-amyrin palmitate	en
dc.subject	Antidyslipidemic activity	en
dc.subject	HMG-CoA reductase inhibitor	en
dc.subject	Cardiovascular disease	en
dc.title	β-Amyrin acetate and β-Amyrin palmitate as antidyslipidemic agents from Wrightia tomentosa leaves	en
dc.type	Article	en